Calla Lily Clinical Care
Calla Lily Clinical Care develops patented medical device technologies engineered to improve intravaginal drug delivery for women's health, focusing on clinical needs such as fertility support, pregnancy management, prevention of recurrent miscarriage, and restoration of the vaginal microbiome. Recognized for innovation, the company maintains collaborative partnerships with clinical and academic institutions and secures funding to advance clinical trials and R&D. Their technology is designed for leak prevention, convenience, and dosing confidence, with a strong commitment to sustainability and social impact as a certified B-Corporation.
Industries
Nr. of Employees
small (1-50)
Calla Lily Clinical Care
Charles House 108-110 Finchley Road London NW3 5JJ UK
Products
Leak-free intravaginal drug delivery device
A patented and FDA-cleared platform for intravaginal delivery of medicines and hormones, utilizing a biocompatible scaffold, mini-liner, and flexible sheath to prevent leakage, enable precise dosage, and facilitate mess-free insertion and removal.
Sample collection device for biomarker diagnostics
Device under development for effective, non-invasive collection of biological samples to support biomarker-based diagnostic tests for gynecological conditions.
Leak-free intravaginal drug delivery device
A patented and FDA-cleared platform for intravaginal delivery of medicines and hormones, utilizing a biocompatible scaffold, mini-liner, and flexible sheath to prevent leakage, enable precise dosage, and facilitate mess-free insertion and removal.
Sample collection device for biomarker diagnostics
Device under development for effective, non-invasive collection of biological samples to support biomarker-based diagnostic tests for gynecological conditions.
Services
Collaboration with academic, NHS, and pharmaceutical partners to design and execute clinical trials evaluating drug delivery devices and platforms in reproductive health.
Development of funding strategies, grant writing, and management of relationships with funding agencies for medical device innovations.
Collaboration with academic, NHS, and pharmaceutical partners to design and execute clinical trials evaluating drug delivery devices and platforms in reproductive health.
Development of funding strategies, grant writing, and management of relationships with funding agencies for medical device innovations.
Expertise Areas
- Women's reproductive health
- Fertility and pregnancy support
- Vaginal microbiome research
- Non-invasive drug delivery
Key Technologies
- Intravaginal drug delivery platforms
- Biocompatible polymer scaffolds
- Leakage prevention device design
- Organ-on-chip technology
News & Updates
Participation in the American Society for Reproductive Medicine Scientific Congress & Expo 2025, showcasing vaginal drug delivery innovation.
Co-founder Dr Lara Zibners participated on the main stage panel at HLTH Vegas, discussing innovation and education in hormone replacement therapy.
Presentation at Women's Health Week conference regarding the development and future impact of the drug delivery platform for women.
Participation in the inaugural Women's Health Horizons (WHH) event, engaging in panels and keynotes on advancing women's health innovation.
Appointment of Dr. Lara Zibners to the Strategic Advisory Board for Women’s Health Horizons (WHH), contributing to women's health strategy.
Attendance at the largest European women's health conference of the year, highlighting the impact of the drug delivery platform in care transformation.
Participation in the American Society for Reproductive Medicine Scientific Congress & Expo 2025, showcasing vaginal drug delivery innovation.
Co-founder Dr Lara Zibners participated on the main stage panel at HLTH Vegas, discussing innovation and education in hormone replacement therapy.
Presentation at Women's Health Week conference regarding the development and future impact of the drug delivery platform for women.
Participation in the inaugural Women's Health Horizons (WHH) event, engaging in panels and keynotes on advancing women's health innovation.
Appointment of Dr. Lara Zibners to the Strategic Advisory Board for Women’s Health Horizons (WHH), contributing to women's health strategy.
Attendance at the largest European women's health conference of the year, highlighting the impact of the drug delivery platform in care transformation.